New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:29 EDTTGTX, HZNP, FPRX, DRNA, ZIOP, EBIO, RGDO, ESPR, KBIO, OMER, ATNMBioCentury to hold a conference
Future Leaders in the Biotech Industry Conference is being held in New York on March 28.
News For ATNM;RGDO;FPRX;OMER;EBIO;HZNP;KBIO;ZIOP;TGTX;ESPR;DRNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 14, 2015
07:31 EDTDRNADicerna announces expansion of ongoing DCR-MYC Phase 1 study
Dicerna Pharmaceuticals announced it is expanding its ongoing Phase 1 study of DCR-MYC in solid tumors, multiple myeloma, or lymphoma to include a cohort of patients with pancreatic neuroendocrine tumors following early signs of clinical and metabolic response and tumor shrinkage in PNET patients. DCR-MYC is an investigational Dicer substrate short-interfering RNA therapeutic targeting the MYC oncogene and the first MYC-targeting short-interfering RNA to enter clinical trials. “Based on the clinical activity seen in two out of three patients with PNET, evidence of a complete metabolic response and a partial response, as well as published evidence on the role of MYC in growth and maintenance of PNET tumors, we are adding a PNET expansion cohort in the ongoing Phase 1 study,” said Pankaj Bhargava, M.D., chief medical officer of Dicerna. The ongoing Phase 1 study, initiated in April 2014, is a multi-center, dose-escalation trial designed to assess the safety and tolerability of DCR-MYC in patients with solid tumors, multiple myeloma, or lymphoma who are refractory or unresponsive to standard therapies. The study is designed to identify the maximum tolerated dose, the pharmacokinetic profile, potential pharmacodynamic effects, and antitumor activity of DCR-MYC. Once the MTD is established, an expansion cohort will be opened to enroll patients with PNET. This multi-center expansion cohort will enroll up to 20 patients with low- to intermediate-grade PNET who have demonstrated disease progression after treatment with standard therapies. Preliminary safety, tolerability, clinical, and metabolic response data from the ongoing Phase 1 trial of DCR-MYC will be presented at the 2015 ASCO Annual Meeting during the Tumor Biology Oral Abstract Session on Monday, June 1.
05:52 EDTZIOPMizuho expects CAR T stocks to be volatile after ASCO abstract
Subscribe for More Information
May 13, 2015
17:33 EDTTGTXTG Therapeutics to present updated data for TG-1101 at ASCO
Subscribe for More Information
17:14 EDTDRNADicerna to present interim data on DCR-MYC at 2015 ASCO annual meeting
Subscribe for More Information
16:21 EDTFPRXFive Prime files to sell $200M of common stock
Subscribe for More Information
16:16 EDTFPRXFive Prime sees FY15 cash at year end $165M-$170M
16:15 EDTFPRXFive Prime reports Q1 EPS (44c), consensus (49c)
Reports Q1 revenue $4.3M, consensus $4.93M.
11:08 EDTHZNPOptions with decreasing implied volatility
Subscribe for More Information
10:02 EDTZIOPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A.O. Smith (AOS) initiated with a Hold at Gabelli... Bellicum Pharmaceuticals (BLCM) initiated with a Neutral at Guggenheim... Criteo (CRTO) initiated with a Hold at Evercore ISI... FleetCor (FLT) initiated with a Buy at Monness Crespi... Franco-Nevada (FNV) initiated with a Buy at Canaccord... Horizon Technology (HRZN) initiated with an Outperform at Oppenheimer... Merrimack (MACK) initiated with a Buy at Guggenheim... Mobileye (MBLY) initiated with a Sector Weight at Pacific Crest... Monroe Capital (MRCC) initiated with an Outperform at Oppenheimer... Royal Gold (RGLD) initiated with a Hold at Canaccord... Silver Wheaton (SLW) initiated with a Buy at Canaccord... U.S. Concrete (USCR) initiated with a Buy at Stifel... Ziopharm (ZIOP) initiated with a Neutral at Guggenheim.
06:47 EDTHZNPHorizon Pharma UCD treatment has upside potential, says Piper Jaffray
After surveying 16 physicians who treat patients with urea cycle disorders, Piper Jaffray sees "ample room" for further growth of Horizon Pharma's Ravicti. Piper believes its Ravicti estimates could prove conservative and reiterates an Overweight rating on Horizon with a $38 price target.
06:26 EDTZIOPZiopharm initiated with a Neutral at Guggenheim
May 12, 2015
10:16 EDTHZNPOptions with decreasing implied volatility
Options with decreasing implied volatility: NDLS WTW FUEL AOL LC NLNK ZU CYBR ARWR HZNP
09:23 EDTZIOPIntrexon CEO says Ziopharm acqusition could be 'attractive' in future
Subscribe for More Information
05:55 EDTZIOPIntrexon price target lowered to $45 from $50 at Mizuho
Subscribe for More Information
May 11, 2015
16:40 EDTOMEROmeros reports Q1 EPS (51c), consensus (63c)
Subscribe for More Information
16:40 EDTZIOPIntrexon declares special dividend of Ziopharm shares
Subscribe for More Information
16:02 EDTDRNADicerna reports Q1 EPS (79c), consensus (73c)
The company stated, "Based on our current cash position and operating plan, the Company re-iterates its expectation that it has sufficient cash to fund operations through 2016. This estimate assumes no additional funding from new partnership agreements or debt or equity financing events."
10:19 EDTHZNPFMR reports 11.4% passive stake in Horizon Pharma
Subscribe for More Information
10:17 EDTHZNPOptions with decreasing implied volatility
Subscribe for More Information
08:18 EDTKBIOKaloBios reports Q1 EPS (29c), consensus (30c)
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use